ReviewFrontiers in oncology2025
Microbiota-host metabolism reprogramming in colorectal cancer: from pathogenesis to precision therapies.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond the barrier: Engineering the tumor-immune-soil nexus-a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer.Medical oncology (Northwood, London, England) · 2026Review
- Low Serum LDL-C Is Associated with Poorer Overall Survival and Lipid-Related Molecular Features in Colorectal Cancer.Biomedicines · 2026Article
- Review
- Traditional Chinese medicine as a potential barrier-oriented sensitization strategy for immune checkpoint blockade in microsatellite-stable colorectal cancer: from resistance mechanisms to translational validation.Frontiers in immunology · 2026Review
- The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer.Frontiers in immunology · 2026Review
- Key messengers in the gut-nose axis: mechanisms of gut microbial metabolites in the immunomodulation of allergic rhinitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a highly aggressive malignancy characterized by complex metabolic reprogramming, a hallmark that provides both biosynthetic precursors and signaling molecules to support tumor growth, invasion and therapeutic resistance. A key mechanism underlying this metabolic rewiring is the dynamic interplay between the host and gut microbiota. Gut microbiota derived metabolites, including short-chain fatty acids, secondary bile acids, polyamines and tryptophan derivatives, extensively reshape the CRC metabolic network and modulate the immune microenvironment, thereby influencing tumor progression and therapy response. This review systematically outlines the core features and molecular mechanisms of metabolic reprogramming in CRC, highlights the role of microbiota-host co-metabolism in regulating energy acquisition and immune-metabolic crosstalk, and discusses emerging therapeutic strategies that integrate metabolic targeting and microbiota modulation for precision intervention in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.